logies that are worthy of development. RVC has already agreed to finance the first (MAR) and is looking at the next two—Prediction Biosciences, and OvationBio. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capit

ogies that are worthy of development. RVC has already agreed to finance the first (MALI) and is looking at the next two—Prediction Biosciences, and OvationBio. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capit

logies that are worthy of development. RVC has already agreed to finance the first (MALI) and is looking at the next two—Prediction Biosciences, and OvationBio. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capit

ologies that are worthy of development. RVC has already agreed to finance the first (MAR) and is looking at the next two—Prediction Biosciences, and OvationBio. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capit

logies that are worthy of development. RVC has already agreed to finance the first (MALI) and is looking at the next two—Prediction Biosciences, and OvationBio. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capit

ologies that are worthy of development. RVC has already agreed to finance the first (MAR) and is looking at the next two—Prediction Biosciences, and OvationBio. I EFTA00357058 have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a

logies that are worthy of development. RVC has already agreed to finance the first (MAJI) and is looking at the next two—Prediction Biosciences, and OvationBio. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capit

logies that are worthy of development. RVC has already agreed to finance the first (MAJI) and is looking at the next two—Prediction Biosciences, and OvationBio. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capit

ly. It will be a challenge to find investors, sensitive to risk and return, to provide OvationBio the capital it needs to do its early work. Somehow OvationBio is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the bigges

ly. It will be a challenge to find investors, sensitive to risk and return, to provide OvationBio the capital it needs to do its early work. Somehow OvationBio is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the bigges

ly. It will be a challenge to find investors, sensitive to risk and return, to provide OvationBio the capital it needs to do its early work. Somehow OvationBio is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the bigges

logies that are worthy of development. RVC has already agreed to finance the first (MALI) and is looking at the next two—Prediction Biosciences, and OvationBio. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capit

logies that are worthy of development. RVC has already agreed to finance the first (MALI) and is looking at the next two—Prediction Biosciences, and OvationBio. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capit

logies that are worthy of development. RVC has already agreed to finance the first (MAJI) and is looking at the next two—Prediction Biosciences, and OvationBio. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capit

ovel manufacturing methods for the production of therapeutic enzymes, and human sequence monoclonal and polyclonal antibodies. • How Does It Work? OvationBio selects the most active and effective protein for our application. By using our proprietary transgenesis technology, we introduce the gene for this

vel manufacturing methods for the production of therapeutic enzymes, and human sequence monoclonal and polyclonal antibodies. • How Does It Work? OvationBio selects the most active and effective protein for our application. By using our proprietary transgenesis technology, we introduce the gene for this